MCID: DFF019
MIFTS: 40

Diffuse Gastric Cancer malady

Categories: Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Diffuse Gastric Cancer

Aliases & Descriptions for Diffuse Gastric Cancer:

Name: Diffuse Gastric Cancer 50
Signet Ring Cell Gastric Carcinoma 50
Signet Ring Gastric Carcinoma 50
Gastric Signet Ring Carcinoma 69
Carcinoma, Signet Ring Cell 69
Signet Ring Cell Carcinoma 50
Signet Cell Adenocarcinoma 50

Classifications:



Summaries for Diffuse Gastric Cancer

NIH Rare Diseases : 50 diffuse gastric cancer or signet ring cell cancer is a type of cancer found most often in the glandular cells lining the stomach, but can also develop in the bowel, breast, pancreas, bladder, prostate or lung. the 2010 who (world health organization) classification recognizes four major histologic patterns of gastric cancers: tubular, papillary, mucinous and poorly cohesive (including signet ring cell carcinoma), plus uncommon histologic variants. the term "signet ring cell" is often used because the cells look like signet rings when viewed under a microscope. the signet cells are a type of epithelial cell. epithelial tissue is skin tissue, covering and lining the body both inside and out. when diffuse gastric cancer is inherited it is called "hereditary diffuse gastric cancer." treatment depends on the stage at which the cancer is found and may include chemotherapy, radiation therapy, or operations to remove the stomach (gastrectomy). last updated: 2/1/2016

MalaCards based summary : Diffuse Gastric Cancer, also known as signet ring cell gastric carcinoma, is related to gastric cancer, somatic and bile duct signet ring cell carcinoma. An important gene associated with Diffuse Gastric Cancer is CDH1 (Cadherin 1), and among its related pathways/superpathways are PAK Pathway and Development HGF signaling pathway. The drugs Vaccines and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and skin, and related phenotypes are integument and neoplasm

Related Diseases for Diffuse Gastric Cancer

Diseases related to Diffuse Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Related Disease Score Top Affiliating Genes
1 gastric cancer, somatic 31.6 CDH1 ERBB2
2 bile duct signet ring cell carcinoma 12.3
3 gastric cancer risk after h. pylori infection 12.1
4 gastric cancer 11.4
5 pancreatic signet ring cell adenocarcinoma 11.3
6 ampullary signet ring cell adenocarcinoma 11.3
7 breast signet ring cell adenocarcinoma 11.3
8 prostate signet ring cell adenocarcinoma 11.3
9 signet ring cell adenocarcinoma 11.3
10 gallbladder signet ring cell adenocarcinoma 11.1
11 prostate cancer 1 11.1
12 prostate cancer 11.1
13 prostate cancer, hereditary, 12 11.1
14 prostate cancer, hereditary, 13 11.1
15 prostate cancer, hereditary, 2 11.1
16 prostate cancer, hereditary, 11 11.1
17 familial stomach cancer 11.0
18 glossopharyngeal motor neuropathy 10.1 CDH1 ERBB2
19 familial renal oncocytoma 10.1 CDH1 CTNNA1
20 basaloid squamous cell carcinoma 10.1 CDH1 ERBB2
21 combined t cell and b cell immunodeficiency 10.1 CDH1 ERBB2
22 acute eustachian salpingitis 10.1 CDH1 CTNNA1
23 nemaline myopathy 8, autosomal recessive 10.1 CDH1 ERBB2
24 gastrointestinal system cancer 10.1 CDH1 ERBB2
25 sclerosing hemangioma 10.1 CDH1 ERBB2
26 retinal disease 10.1 CDH1 ERBB2
27 estrogen-receptor positive breast cancer 10.1 CDH1 ERBB2
28 ileocolitis 10.1 CDH1 IL1B
29 pyomyositis 10.1 CDH1 ERBB2
30 dental caries 10.1 CDH1 ERBB2
31 chondrodysplasia punctata, rhizomelic, type 1 10.1 CDH1 IL1B
32 amyotrophic lateral sclerosis type 14 10.1 CDH1 IL1B
33 nasal cavity disease 10.1 CDH1 ERBB2
34 progesterone-receptor positive breast cancer 10.1 CDH1 ERBB2
35 odontotrichoungual-digital-palmar syndrome 10.1 CDH1 ERBB2
36 spindle cell hemangioma 10.1 ERBB2 IL1B
37 tenosynovitis of foot and ankle 10.1 CDH1 ERBB2
38 pearson syndrome 10.0 CDH1 ERBB2
39 mikulicz disease 10.0 ERBB2 IL1B
40 trachea squamous cell carcinoma 10.0 CDH1 ERBB2
41 dysembryoplastic neuroepithelial tumor 10.0 CDH1 ERBB2
42 breast malignant phyllodes tumor 10.0 CDH1 ERBB2
43 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.0 CDH1 ERBB2
44 bardet-biedl syndrome 10.0 CDH1 ERBB2
45 facial dermatosis 9.9 CDH1 ERBB2
46 substance abuse 9.9 CDH1 CTNNA1 ERBB2
47 hepatocellular carcinoma 9.9 CDH1 CTNNA1 IL1B
48 solitary plasmacytoma of chest wall 9.9 CDH1 ERBB2
49 breast cancer 9.8
50 cleft lip 9.7

Graphical network of the top 20 diseases related to Diffuse Gastric Cancer:



Diseases related to Diffuse Gastric Cancer

Symptoms & Phenotypes for Diffuse Gastric Cancer

MGI Mouse Phenotypes related to Diffuse Gastric Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.26 ERBB2 IL1B CDH1 CTNNA1
2 neoplasm MP:0002006 8.92 CDH1 CTNNA1 ERBB2 IL1B

Drugs & Therapeutics for Diffuse Gastric Cancer

Drugs for Diffuse Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 1
2
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
3
Fluorouracil Approved Phase 2, Phase 3, Phase 1 51-21-8 3385
4
Levoleucovorin Approved Phase 3,Phase 1,Phase 2 68538-85-2
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
7
Ramucirumab Approved, Investigational Phase 2, Phase 3 947687-13-0
8 Tegafur Approved Phase 3 17902-23-7
9
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
10
Docetaxel Approved May 1996, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124 9877265
11 Liver Extracts Phase 3,Phase 2,Phase 1
12 Antimetabolites Phase 2, Phase 3, Phase 1
13 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
14 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
15 Antidotes Phase 3,Phase 1,Phase 2
16 Calcium, Dietary Phase 3,Phase 1,Phase 2
17 Protective Agents Phase 3,Phase 1,Phase 2
18 Adjuvants, Anesthesia Phase 3
19 Analgesics Phase 3,Phase 1,Phase 2
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Central Nervous System Depressants Phase 3
25 Narcotics Phase 3
26 pancreatic polypeptide Phase 3
27 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
28 Antibodies Phase 2, Phase 3,Phase 1
29 Antibodies, Monoclonal Phase 2, Phase 3
30 Antimitotic Agents Phase 2, Phase 3,Phase 1
31 Immunoglobulins Phase 2, Phase 3,Phase 1
32
s 1 (combination) Phase 3
33 Cola Nutraceutical Phase 3,Phase 2,Phase 1
34
Indinavir Approved Phase 2 150378-17-9 5362440
35
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
36
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
37
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
38
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
39
Bevacizumab Approved, Investigational Phase 2 216974-75-3
40
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
41
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
42
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
43
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
44
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
45
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
46
rituximab Approved Phase 2 174722-31-7 10201696
47
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
48
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613 2171
49
Clarithromycin Approved Phase 2 81103-11-9 84029
50
Metronidazole Approved Phase 2,Phase 1 443-48-1 4173

Interventional clinical trials:

(show top 50) (show all 58)
id Name Status NCT ID Phase
1 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
2 Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases Completed NCT02219529 Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
4 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Diffuse Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3
5 FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Recruiting NCT02661971 Phase 2, Phase 3
6 Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial Active, not recruiting NCT01285557 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Terminated NCT00004099 Phase 3
8 C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Unknown status NCT02344810 Phase 1, Phase 2
9 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
10 Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients Completed NCT02575859 Phase 1, Phase 2
11 Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer Completed NCT01260701 Phase 2
12 S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer Completed NCT00103324 Phase 2
13 Irinotecan in Treating Patients With Advanced Cancer of the Stomach Completed NCT00003137 Phase 2
14 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma Completed NCT00084617 Phase 2
15 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach Completed NCT00061932 Phase 2
16 Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Completed NCT00991952 Phase 2
17 Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00084604 Phase 2
18 Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer Completed NCT01231399 Phase 1, Phase 2
19 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2
20 Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma Completed NCT00204659 Phase 2
21 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Recruiting NCT02900651 Phase 1, Phase 2
22 PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Recruiting NCT03044743 Phase 1, Phase 2
23 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Recruiting NCT02178722 Phase 1, Phase 2
24 First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL Recruiting NCT02388581 Phase 2
25 Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer Active, not recruiting NCT01212822 Phase 2
26 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Not yet recruiting NCT02978625 Phase 2
27 Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas Suspended NCT01723306 Phase 2
28 A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer Terminated NCT00064259 Phase 1, Phase 2
29 Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma Terminated NCT00057954 Phase 2
30 Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Completed NCT00028496 Phase 1
31 Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer Completed NCT00027534 Phase 1
32 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
33 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
34 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
35 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1
36 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
37 Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma Completed NCT01165333 Phase 1
38 A Phase I Trial of AZD3965 in Patients With Advanced Cancer Recruiting NCT01791595 Phase 1
39 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Recruiting NCT01643499 Phase 1
40 Idelalisib Post Allogeneic BMT in B Cell Derived Malignancies: A Phase 1 Toxicity Trial Recruiting NCT03151057 Phase 1
41 Tamoxifen in Patients With Oesophageal Cancer Recruiting NCT02513849 Phase 1
42 Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat Not yet recruiting NCT03028103 Phase 1
43 Lauren Classifications and HER2 Status in Gastric Cancer Patients Unknown status NCT01927146
44 Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma Completed NCT01824966
45 Prognosis of Signet Ring Cells in Upper Digestive Neoplasms Completed NCT01249859
46 NBI for Identifying Resection Margin Status in Gastric Cancer Completed NCT02926716
47 Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma Completed NCT02731313
48 Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery Completed NCT01612546
49 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514
50 Colon Capsule Versus Virtual Colonoscopy for Colorectal Cancer Screening Completed NCT02558881

Search NIH Clinical Center for Diffuse Gastric Cancer

Genetic Tests for Diffuse Gastric Cancer

Anatomical Context for Diffuse Gastric Cancer

MalaCards organs/tissues related to Diffuse Gastric Cancer:

39
Breast, Lung, Skin, Prostate, Pancreas, Testes

Publications for Diffuse Gastric Cancer

Articles related to Diffuse Gastric Cancer:

(show top 50) (show all 139)
id Title Authors Year
1
An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). ( 27256430 )
2016
2
Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. ( 27573781 )
2016
3
Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer. ( 27909811 )
2016
4
MicroRNAs in hereditary diffuse gastric cancer. ( 27446532 )
2016
5
Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer. ( 28008412 )
2016
6
Erratum to: Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. ( 27778307 )
2016
7
Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. ( 27759617 )
2016
8
The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC). ( 27837291 )
2016
9
PanelA testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer. ( 27064202 )
2016
10
A novel mutation in the CDH1 gene in a Spanish family with hereditary diffuse gastric cancer. ( 27512640 )
2016
11
Early diagnosis of hereditary diffuse gastric cancer: (not only) an endoscopic challenge! ( 27995194 )
2016
12
Cate's Story: Hereditary Diffuse Gastric Cancer. ( 27441520 )
2016
13
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. ( 25979631 )
2015
14
Hereditary diffuse gastric cancer: What the clinician should know. ( 26380059 )
2015
15
1229: BEYOND HELLP: PERIPARTUM CATASTROPHIC THROMBOEMBOLISM DUE TO HEREDITARY DIFFUSE GASTRIC CANCER. ( 26570890 )
2015
16
Association between Promoter Polymorphisms of TFF1, TFF2, and TFF3 and the Risk of Gastric and Diffuse Gastric Cancers in a Korean Population. ( 26240479 )
2015
17
Hereditary diffuse gastric cancer: laparoscopic surgical approach associated to rare mutattion of CDH1 gene. ( 26176257 )
2015
18
Error in Byline. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. ( 26182313 )
2015
19
Recognition of and recent issues in hereditary diffuse gastric cancer. ( 26049741 )
2015
20
Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. ( 26182300 )
2015
21
Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer. ( 25576241 )
2015
22
[Hereditary diffuse gastric cancer]. ( 25875520 )
2015
23
Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1. ( 26072394 )
2015
24
Hereditary diffuse gastric cancer--An overview. ( 26150395 )
2015
25
Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation. ( 26025002 )
2015
26
CDH1 germ-line missense mutation identified by multigene sequencing in a family with no history of diffuse gastric cancer. ( 25981591 )
2015
27
Genetic screening analysis of patients with hereditary diffuse gastric cancer from northern and northeastern Brazil. ( 25180051 )
2014
28
RhoA mutations identified in diffuse gastric cancer. ( 25026207 )
2014
29
Detection of CDH1 gene variants in early-onset diffuse gastric cancer in Chinese patients. ( 25648022 )
2014
30
Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. ( 25315765 )
2014
31
Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. ( 24472763 )
2014
32
Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study. ( 24389957 )
2014
33
Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome. ( 24493355 )
2014
34
Hereditary diffuse gastric cancer associated with E-cadherin germline mutation: a case report. ( 25089230 )
2014
35
Hereditary diffuse gastric cancer - pathophysiology and clinical management. ( 25439071 )
2014
36
pRb2/p130 is Delocalized in Cytoplasm in Diffuse Gastric Cancer: A Preliminary Study. ( 25205458 )
2014
37
Association between the epithelial cadherin -160C/A gene polymorphism and diffuse gastric cancer risk: a meta-analysis. ( 24615049 )
2014
38
E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. ( 23481202 )
2013
39
Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene. ( 23812922 )
2013
40
Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. ( 23264079 )
2013
41
Frequent promoter methylation of CDH1 in non-neoplastic mucosa of sporadic diffuse gastric cancer. ( 24023308 )
2013
42
Hereditary diffuse gastric cancer in a Japanese family with a large deletion involving CDH1. ( 24037103 )
2013
43
Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). ( 23443028 )
2013
44
Laparoscopic prophylactic total gastrectomy with linear stapler side-to-side esophagojejunal anastomosis for hereditary diffuse gastric cancer syndrome in 2 siblings. ( 23752020 )
2013
45
Cleft lip, cleft palate, hereditary diffuse gastric cancer and germline mutations in CDH1. ( 23124477 )
2013
46
Hereditary diffuse gastric cancer: a family diagnosis and treatment. ( 22723466 )
2013
47
An I+-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. ( 23208944 )
2013
48
Catenin family genes are not commonly mutated in hereditary diffuse gastric cancer. ( 23071139 )
2012
49
E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer. ( 22470475 )
2012
50
Hereditary diffuse gastric cancer: the always-forgotten Meckel's diverticulum. ( 22240148 )
2012

Variations for Diffuse Gastric Cancer

Cosmic variations for Diffuse Gastric Cancer:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM18885 APC breast,NS,carcinoma,tubular c.4495G>T p.G1499* 8
2 COSM18876 APC breast,NS,carcinoma,tubular c.3316G>T p.G1106* 8
3 COSM18881 APC breast,NS,carcinoma,tubular c.5047G>T p.E1683* 8
4 COSM18883 APC breast,NS,carcinoma,tubular c.4390G>T p.E1464* 8

Expression for Diffuse Gastric Cancer

Search GEO for disease gene expression data for Diffuse Gastric Cancer.

Pathways for Diffuse Gastric Cancer

Pathways related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 CDH1 CTNNA1 ERBB2 IL1B
2
Show member pathways
12.39 CDH1 CTNNA1 ERBB2
3 12.28 CDH1 CTNNA1 ERBB2
4
Show member pathways
11.79 CDH1 CTNNA1 ERBB2
5
Show member pathways
11.67 ERBB2 IL1B
6 11.61 CDH1 CTNNA1
7 11.44 CDH1 CTNNA1
8 11.43 CDH1 IL1B
9 11.4 CDH1 ERBB2
10 11.14 CDH1 CTNNA1
11 11.06 CDH1 CTNNA1
12 11.03 CDH1 CTNNA1
13 10.92 CDH1 CTNNA1
14 10.86 CDH1 ERBB2
15 10.72 CDH1 CTNNA1
16 10.66 CDH1 CTNNA1 ERBB2
17 10.43 CDH1 CTNNA1
18 10.07 CDH1 CTNNA1

GO Terms for Diffuse Gastric Cancer

Cellular components related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell-cell adherens junction GO:0005913 9.16 CDH1 CTNNA1
2 catenin complex GO:0016342 8.96 CDH1 CTNNA1
3 flotillin complex GO:0016600 8.62 CDH1 CTNNA1

Biological processes related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 adherens junction organization GO:0034332 9.26 CDH1 CTNNA1
2 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.16 CTNNA1 IL1B
3 axon regeneration GO:0031103 8.96 CTNNA1 MTR
4 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNA1

Molecular functions related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-catenin binding GO:0008013 8.96 CDH1 CTNNA1
2 gamma-catenin binding GO:0045295 8.62 CDH1 CTNNA1

Sources for Diffuse Gastric Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....